Page last updated: 2024-12-05

tropicamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Tropicamide: One of the MUSCARINIC ANTAGONISTS with pharmacologic action similar to ATROPINE and used mainly as an ophthalmic parasympatholytic or mydriatic. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5593
CHEMBL ID1200604
CHEBI ID9757
SCHEMBL ID23975
MeSH IDM0022036

Synonyms (194)

Synonym
AC-816
tropicamide [usan:usp:inn:ban:jan]
tropicamida
unii-n0a3z5xtc6
n0a3z5xtc6 ,
5-22-09-00359 (beilstein handbook reference)
nsc 757372
MLS002154240
HMS3267A13
AB00052120-10
BRD-A79672927-001-05-8
DIVK1C_000448
KBIO1_000448
EU-0101223
tropicamide, solid
SPECTRUM_000584
SPECTRUM5_001585
IDI1_000448
(+-)-n-ethyl-2-phenyl-n-(4-pyridylmethyl)hydracrylamide
mydriafair
n-ethyl-alpha-(hydroxymethyl)-n-(4-pyridinylmethyl)benzeneacetamide
tropicamida [inn-spanish]
mydrum
brn 0285563
n-ethyl-2-phenyl-n-(4-pyridylmethyl)hydracrylamide
epitromina
mydriaticum
einecs 216-140-2
tropimil
benzeneacetamide, n-ethyl-alpha-(hydroxymethyl)-n-(4-pyridinylmethyl)-, (+-)-
visumidriatic
hydracrylamide, n-ethyl-2-phenyl-n-(4-pyridylmethyl)-
mydriacyl
n-ethyl-n-(4-pyridylmethyl)tropamide
tropikamid
minims tropicamide
bistropamide
n-ethyl-n-(4-pyridylmethyl)tropamid
benzeneacetamide, n-ethyl-alpha-(hydroxymethyl)-n-(4-pyridinylmethyl)-
tropicamidum [inn-latin]
ro 1-7683
tropicacyl
benzeneacetamide, n-ethyl-.alpha.-(hydroxymethyl)-n-(4-pyridinylmethyl)-
1508-75-4
tropicamide
PRESTWICK_487
cas-1508-75-4
BPBIO1_000303
SMP1_000304
LOPAC0_001223
PRESTWICK3_000228
BSPBIO_002289
BSPBIO_000275
AB00052120
DB00809
tropicamide (jp17/usp/inn)
mydriacyl (tn)
D00397
NCGC00024866-04
NCGC00024866-03
NCGC00024866-06
KBIO3_001509
KBIOSS_001064
KBIO2_001064
KBIO2_003632
KBIO2_006200
KBIOGR_000873
PRESTWICK0_000228
SPECTRUM4_000377
SPBIO_000872
SPECTRUM3_000655
SPECTRUM2_000936
SPBIO_002196
NINDS_000448
PRESTWICK1_000228
SPECTRUM1500599
PRESTWICK2_000228
MLS001306442
smr000058523
NCGC00024866-05
NCGC00024866-02
NCGC00016065-03
HMS2092A18
HMS2089M05
T 9778 ,
NCGC00016065-08
CHEMBL1200604
nsc-757372
ro-1-7683
tropicamidum
L001262
tropicamid
HMS501G10
FT-0657590
T1470
HMS1568N17
HMS1921I09
n-ethyl-3-hydroxy-2-phenyl-n-(pyridin-4-ylmethyl)propanamide
NCGC00016065-07
HMS3263F08
HMS2095N17
HMS3259M18
pharmakon1600-01500599
nsc757372
tox21_110297
dtxsid8045220 ,
dtxcid6025220
bdbm82371
nsc_5593
cas_1508-75-4
HMS2235J15
STK934612
CCG-40076
NCGC00016065-06
NCGC00016065-09
NCGC00016065-04
NCGC00016065-05
AKOS005664076
opticyl
LP01223
AM84467
S1913
HMS3373B07
gtpl7319
tropicamide [vandf]
tropicamide [who-dd]
tropicamidum [who-ip latin]
tropicamide [jan]
tropicamide [usp monograph]
tropicamide [orange book]
tropicamide [mart.]
benzeneacetamide, n-ethyl-.alpha.-(hydroxymethyl)-n-(4-pyridinylmethyl)-, (+/-)-
tropicamide [who-ip]
tropicamide [inn]
mydcombi component tropicamide
tropicamide component of mydcombi
tropicamide component of paremyd
tropicamide [usan]
tropicamide [mi]
(+/-)-n-ethyl-2-phenyl-n-(4-pyridylmethyl)hydracrylamide
paremyd component tropicamide
tropicamide [ep monograph]
tropicamide [usp-rs]
HY-B0321
NC00589
BBL028074
SCHEMBL23975
tox21_110297_1
NCGC00016065-11
KS-5174
NCGC00261908-01
tox21_501223
Q-201902
n-ethyl-3-hydroxy-2-phenyl-n-(4-pyridinylmethyl)propanamide #
component of paremyd
AB00052120_11
AB00052120_12
mfcd00058580
sr-01000075351
SR-01000075351-1
tropicamide, united states pharmacopeia (usp) reference standard
HMS3651K04
tropicamide for peak identification, european pharmacopoeia (ep) reference standard
tropicamide, european pharmacopoeia (ep) reference standard
CHEBI:9757
SR-01000075351-3
SR-01000075351-5
SR-01000075351-7
SBI-0051190.P003
HMS3712N17
SW196691-3
HMS3675F14
BCP13504
HMS3411F14
Q29310
BRD-A79672927-001-10-8
SDCCGSBI-0051190.P004
NCGC00016065-22
HMS3884E16
HMS3742C05
C72868
n-ethyl-2-phenyl-n-(4-pyridylmethyl hydracrylamide
EN300-7357022
n-ethyl-3-hydroxy-2-phenyl-n-[(pyridin-4-yl)methyl]propanamide
tropicamide for peak identification
tropicamide (ep monograph)
tropicamide (usan:usp:inn:ban:jan)
tropicamida (inn-spanish)
tropicamidum (inn-latin)
l-picamide
s01fa06
tropicamide (usp monograph)
tropicamide (usp-rs)
tropicamide (mart.)

Research Excerpts

Overview

Tropicamide is an antimuscarinic ophthalmic solution used to produce short-acting mydriasis and cycloplegia. Tropicamide (1%) is an effective Cycloplegic agent in myopic children.

ExcerptReferenceRelevance
"Tropicamide is an antimuscarinic drug usually prescribed as an ophthalmic solution to induce short-term mydriasis and cycloplegia. "( Drops of madness? Recreational misuse of tropicamide collyrium; early warning alerts from Russia and Italy.
Bersani, FS; Corazza, O; Levari, E; Lovaste, R; Mylokosta, A; Schifano, F; Simonato, P,
)
1.84
"Tropicamide is an antimuscarinic ophthalmic solution used to produce short-acting mydriasis and cycloplegia. "( Intravenous Abuse of Tropicamide in Opioid Use Disorder: Presentation of 2 Cases.
Bozkurt, M; Evren, C; Kan, H; Karabulut, V; Seker, M, 2015
)
2.18
"Tropicamide is a weak cycloplegic."( [Objective refraction in black children: cyclopentolate and tropicamide combination, a reliable alternative to atropine?].
Ba, EA; De Medeiros, ME; Diagne, JP; Diallo, HM; Ka, AM; Kane, A; Ndiaye, JM; Ndiaye, MR; Ndiaye, PA; Ndoye Roth, PA; Sow, AS; Wane, AM; Weladji, C, 2014
)
1.37
"Tropicamide is a mydriatic drug used as eye-drops for diagnostic or therapeutic purposes. "( Early signal of diverted use of tropicamide eye drops in France.
Jouanjus, E; Lapeyre-Mestre, M; Palmaro, A; Pi, C; Ponté, C, 2017
)
2.18
"Tropicamide is a short-acting atropine-like derivative and has been regarded as an effective and safe mydriatic."( Near fatal anticholinergic intoxication after routine fundoscopy.
Brunner, GA; Brussee, H; Fleck, S; Kaufmann, P; Krejs, GJ; Lueger, A; Pieber, TR; Smolle, KH, 1998
)
1.02
"Tropicamide (1%) is an effective cycloplegic agent in myopic children."( Tropicamide (1%): an effective cycloplegic agent for myopic children.
Hussein, M; Kurtz, D; Manny, RE; Niemann, K; Scheiman, M; Zinzer, K, 2001
)
3.2

Toxicity

ExcerptReferenceRelevance
"Cycloplegics are very safe and useful medications."( Avoiding adverse effects of cycloplegics in infants and children.
Gray, LG, 1979
)
0.26
"A drug registry was established at Southern California College of Optometry (SCCO) to study use rates and incidence of adverse side effects of the nine pharmaceutical agents in the California optometry law."( Use of diagnostic pharmaceutical agents and incidence of adverse effects.
Applebaum, M; Jaanus, SD, 1983
)
0.27
" Both regimens were safe with regard to their cardiovascular effects."( Randomized clinical trial of the efficacy and safety of tropicamide and phenylephrine in preoperative mydriasis for phacoemulsification.
Chi, SC; Lam, DS; Lam, PT; Poon, BT; Wu, WK, 2003
)
0.57
"Intracameral injection of Mydrin-P appears to be effective and safe for dilating the pupil in cases with poor mydriasis after preoperative instillation of mydriatics."( Intraoperative mydriasis by intracameral injection of mydriatic eye drops: in vivo efficacy and in vitro safety studies.
Amano, S; Kagaya, F; Miyai, T; Miyata, K; Mori, Y; Nagai, N; Osakabe, Y, 2011
)
0.37
" No adverse events were detected in any of the treatment sequences."( A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients.
Carrosella, A; Gamzu, E; Lloret, SP; Merello, M; Nano, G, 2011
)
0.57
"Results of this pilot, proof-of-concept study show that NH004 was safe and exerted antisialorrhea effects worthy of further exploration."( A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients.
Carrosella, A; Gamzu, E; Lloret, SP; Merello, M; Nano, G, 2011
)
0.57
" A total of 154 eyes of 77 patients were randomly divided into 2 groups: group 1 consisted of 78 eyes, group 2 consisted of 76 eyes, and the patients were monitored for pupillary dilation, blood pressure, heart rate, and possible adverse effects at 0, 20, 40, 60, and 90 minutes."( Evaluation of the efficacy and safety of the ophthalmic insert Mydriasert in patients undergoing retinal angiography.
Cagini, C; Caricato, A; Cesari, C; Fiore, T; Pascale, A; Tosi, G,
)
0.13
"No severe adverse effects were observed in either group."( Evaluation of the efficacy and safety of the ophthalmic insert Mydriasert in patients undergoing retinal angiography.
Cagini, C; Caricato, A; Cesari, C; Fiore, T; Pascale, A; Tosi, G,
)
0.13
" No serious side effect could be ascribed to the use of phenylephrine 5% eye drops in this study."( [Serious adverse side effects after pupillary dilation in preterm infants].
Denion, E; Fedrizzi, S; Guillois, B; Lux, AL; Mouriaux, F; Peyro-Saint-Paul, L, 2015
)
0.42
"Mydrane is an effective and safe alternative to standard eye drops for initiating and maintaining intraoperative mydriasis and analgesia."( Evaluation of the efficacy and safety of a standardised intracameral combination of mydriatics and anaesthetics for cataract surgery.
Alió, J; Behndig, A; Cochener, B; Colin, J; Findl, O; Hartani, D; Labetoulle, M; Lazreg, S; Lobo, C; Malecaze, F; Tassignon, MJ, 2016
)
0.43
"5% drop is effective and safe as mydriatic combination for retinopathy of prematurity screening."( Efficiency and safety of phenylephrine and tropicamide used in premature retinopathy: a prospective observational study.
Alpay, A; Aydemir, C; Canturk Ugurbas, S, 2019
)
0.78
"To evaluate systemic adverse events after screening for retinopathy of prematurity (ROP) performed with mydriatic."( Systemic adverse events after screening of retinopathy of prematurity with mydriatic.
Imamura, T; Kakinoki, M; Maruo, Y; Obata, S; Ohji, M; Yanagi, T, 2021
)
0.62
" The numbers of infants with abdominal and/or systemic adverse events were compared between pre- and post-examination periods."( Systemic adverse events after screening of retinopathy of prematurity with mydriatic.
Imamura, T; Kakinoki, M; Maruo, Y; Obata, S; Ohji, M; Yanagi, T, 2021
)
0.62
"Screening for ROP with mydriatic may have adverse effects on systemic conditions."( Systemic adverse events after screening of retinopathy of prematurity with mydriatic.
Imamura, T; Kakinoki, M; Maruo, Y; Obata, S; Ohji, M; Yanagi, T, 2021
)
0.62
" Otherwise, adverse events did not differ after either administration technique."( Efficacy and safety of mydriatic microdrops for retinopathy of prematurity screening: an external pilot crossover randomized controlled trial.
Diamanti, E; Georgiou, E; Haidich, AB; Lithoxopoulou, M; Mataftsi, A; Seliniotaki, AK; Talimtzi, P; Ziakas, N, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
" An examiner masked to drug combination and time used digital analysis to calculate pupil diameter for each photograph."( Comparison of two drug combinations for dilating dark irides.
Anderson, HA; Bertrand, KC; Fern, KD; Hu, YS; Manny, RE, 2010
)
0.36

Bioavailability

Mucoadhesive polymer-coated vesicles failed to increase significantly the bioavailability of the entrapped tropicamide. The area under the mydriatic response-time curve (AUC 0-6 hr) was interpreted as an indication of theBioavailability of tropicamia in each vehicle.

ExcerptReferenceRelevance
" Mucoadhesive polymer-coated vesicles failed to increase significantly the bioavailability of the entrapped tropicamide compared to uncoated vesicles and aqueous solution."( Evaluation of mucoadhesive polymers in ocular drug delivery. II. Polymer-coated vesicles.
Davies, NM; Farr, SJ; Hadgraft, J; Kellaway, IW, 1992
)
0.5
" The area under the mydriatic response-time curve (AUC 0-6 hr) was interpreted as an indication of the bioavailability of tropicamide in each vehicle."( Enhancement of the mydriatic response to tropicamide by bioadhesive polymers.
Cadórniga, R; Fernandez-Carballido, A; Frutos, G; Herrero-Vanrell, R, 2000
)
0.78
" The advantages of NH004 include local bioavailability with low systemic exposure, rapid onset of action and, importantly, convenience of use for patients."( Design and development of a novel supportive care product for the treatment of sialorrhea in Parkinson's disease.
Farber, NM; Gamzu, ER; Perez-Lloret, S, 2015
)
0.42
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Pupil dilation assay by tropicamide is not an effective diagnostic tool for AD. It may be modulated by different gene dosage of ApoE epsilon 4.6.

ExcerptRelevanceReference
" The above agents, used individually for a total dosage of three drops in each eye did not provide adequate dilation for a thorough funduscopic examination."( Systemic response to mydriatic eyedrops in neonates: mydriatics in neonates.
Caputo, AR; Schnitzer, RE,
)
0.13
"We studied the effects of multiple dosing and pre-instilled mydriatics (0."( [Effects of pre-instilled mydriatics on the intraocular concentration and anti-inflammatory action of topical 0.1% pranoprofen (2)--Study on multiple dosing].
Ogawa, T; Ohara, K; Shimizu, H, 1992
)
0.28
" Adverse effects are often related to dosage or other factors."( Mydriatic and cycloplegic drugs: a review of ocular and systemic complications.
Doughty, CB; Rengstorff, RH, 1982
)
0.26
" Using testing conditions of both normal (35 ft-c) and bright (150 ft-c) illumination, no mydriatic dose-response differences for the four concentrations were found."( Dose-response effects of tropicamide HCl.
Hunt, JS; Pollack, SL; Polse, KA, 1981
)
0.57
"This study indicates that a lower dosage (for example, one drop) is also efficacious and has the added benefit of fewer side effects."( Comparison of the effects on pupil size and accommodation of three regimens of topical dapiprazole.
Crowder, AM; Dale, JL; Heiser, JF; Katz, BB; Wassom, NJ; Wilcox, CS, 1995
)
0.29
"6) was examined to evaluate the dose-response effect and time course on pupil diameter, of ibopamine, phenylephrine, and tropicamide."( Comparative study of the effects of 2% ibopamine, 10% phenylephrine, and 1% tropicamide on the anterior segment.
Babighian, S; Bonomi, L; Marchini, G; Perfetti, S; Tosi, R, 2003
)
0.76
"An isocratic, reversed-phase liquid chromatographic method was developed for determination of tropicamide using atropine as an internal standard in a pharmaceutical dosage form."( Determination of tropicamide in pharmaceutical formulations using high-performance liquid chromatography.
Amanlou, M; Andalibi, PC; Asmardi, G; Javadi, N; Khodadady, F; Omarny, ZB, 2005
)
0.89
" That some patients still yielded to acute organophosphate poisoning despite repeated dosing of atropine suggests that cellular mechanisms that are independent of muscarinic receptor activation may also be engaged in organophosphate poisoning."( Muscarinic receptor-independent activation of cyclic adenosine monophosphate-dependent protein kinase in rostral ventrolateral medulla underlies the sympathoexcitatory phase of cardiovascular responses during mevinphos intoxication in the rat.
Chan, SH; Chang, AY; Tsai, CY; Wu, CH, 2007
)
0.34
" Analysis of the dose-response curves indicated that tropicamide showed approximately the same potency as atropine for suppression of pilocarpine-induced jaw movements but was more potent than atropine on the suppression of pimozide-induced jaw movements."( The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors.
Betz, AJ; Burgos, M; McLaughlin, PJ; Salamone, JD; Weber, SM, 2007
)
0.87
" Dose-response curves for steady-state pupil size and for behavioral phase shifts were constructed for 3 pupil conditions (dilated, constricted, and control)."( Photic sensitivity ranges of hamster pupillary and circadian phase responses do not overlap.
Cooper, HM; Hut, RA; Oklejewicz, M; Rieux, C, 2008
)
0.35
"5 years) and the dose-response setting, 10 volunteers (mean age 24."( Mydriasis with different preparations of topically administered lidocaine hydrochloride.
Behndig, A; Claesson, M; Johansson, M, 2009
)
0.35
" However, the release kinetic was significantly influenced by the method used, highlighting the need for optimization and standardization of in vitro models for the evaluation of drug release from ophthalmic dosage forms."( Mydriatics release from solid and semi-solid ophthalmic formulations using different in vitro methods.
Gioia, GA; Macaluso, C; Nicoli, S; Padula, C; Pescina, S; Santi, P, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
acetamidesCompounds with the general formula RNHC(=O)CH3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (26)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
endonuclease IVEscherichia coliPotency0.70790.707912.432431.6228AID1708
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.11220.100020.879379.4328AID588453
RAR-related orphan receptor gammaMus musculus (house mouse)Potency29.84930.006038.004119,952.5996AID1159521
USP1 protein, partialHomo sapiens (human)Potency56.23410.031637.5844354.8130AID743255
Microtubule-associated protein tauHomo sapiens (human)Potency17.58550.180013.557439.8107AID1468
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency10.22780.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency6.00700.000214.376460.0339AID720691
GVesicular stomatitis virusPotency1.62340.01238.964839.8107AID1645842
arylsulfatase AHomo sapiens (human)Potency37.93301.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.16830.035520.977089.1251AID504332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency29.84930.001723.839378.1014AID743083
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00350.540617.639296.1227AID2364; AID2528
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency7.94330.794321.275750.1187AID624246
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency11.42390.005612.367736.1254AID624032
Interferon betaHomo sapiens (human)Potency1.62340.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency1.62340.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency1.62340.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency1.62340.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)150.90000.11007.190310.0000AID1449628
Muscarinic acetylcholine receptor M2Homo sapiens (human)IC50 (µMol)0.10500.00001.23267.7930AID625152
Muscarinic acetylcholine receptor M2Homo sapiens (human)Ki0.03700.00000.690210.0000AID625152
Muscarinic acetylcholine receptor M4Homo sapiens (human)IC50 (µMol)0.02500.00001.15467.5858AID625154
Muscarinic acetylcholine receptor M4Homo sapiens (human)Ki0.00350.00000.79519.1201AID625154
Muscarinic acetylcholine receptor M5Homo sapiens (human)IC50 (µMol)0.08900.00010.99178.0000AID625155
Muscarinic acetylcholine receptor M5Homo sapiens (human)Ki0.06400.00000.72926.9183AID625155
Muscarinic acetylcholine receptor M1Homo sapiens (human)IC50 (µMol)0.28100.00001.403910.0000AID625151
Muscarinic acetylcholine receptor M1Homo sapiens (human)Ki0.06800.00000.59729.1201AID625151
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)1.00000.00002.800510.0000AID625248
Muscarinic acetylcholine receptor M3Homo sapiens (human)IC50 (µMol)0.14200.00011.01049.9280AID625153
Muscarinic acetylcholine receptor M3Homo sapiens (human)Ki0.03000.00000.54057.7600AID625153
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)1.00000.00002.398310.0000AID625247
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (118)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of heart contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
response to virusMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M2Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M4Homo sapiens (human)
cell surface receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M4Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M4Homo sapiens (human)
gastric acid secretionMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
dopamine transportMuscarinic acetylcholine receptor M5Homo sapiens (human)
transmission of nerve impulseMuscarinic acetylcholine receptor M5Homo sapiens (human)
regulation of phosphatidylinositol dephosphorylationMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M5Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M5Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
positive regulation of monoatomic ion transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
neuromuscular synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M1Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M1Homo sapiens (human)
cognitionMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of postsynaptic membrane potentialMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of glial cell proliferationMuscarinic acetylcholine receptor M1Homo sapiens (human)
positive regulation of intracellular protein transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
calcium-mediated signalingMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
synaptic transmission, cholinergicMuscarinic acetylcholine receptor M3Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of insulin secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein modification processMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ligand-gated ion channel signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M3Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (47)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
arrestin family protein bindingMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
signaling receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (44)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
clathrin-coated endocytic vesicle membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
asymmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
symmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
neuronal cell bodyMuscarinic acetylcholine receptor M2Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M2Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M5Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M5Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M1Homo sapiens (human)
Schaffer collateral - CA1 synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic density membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
endoplasmic reticulum membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basal plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basolateral plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M3Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (81)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (635)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990101 (15.91)18.7374
1990's137 (21.57)18.2507
2000's147 (23.15)29.6817
2010's174 (27.40)24.3611
2020's76 (11.97)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 81.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index81.35 (24.57)
Research Supply Index6.74 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index145.91 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (81.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials148 (21.23%)5.53%
Reviews20 (2.87%)6.00%
Case Studies46 (6.60%)4.05%
Observational10 (1.43%)0.25%
Other473 (67.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (29)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia [NCT03201562]Phase 258 participants (Actual)Interventional2017-04-30Completed
A Multi-Center, Double-Masked, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Fixed Combination Phenylephrine 2.5%-Tropicamide 1% Ophthalmic Solution Administered With a Microdose Dispenser for Dilation of the Pupil [NCT03751098]Phase 376 participants (Actual)Interventional2018-12-01Completed
The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients, Pressure Control and Pupil Effects [NCT03139708]Phase 15 participants (Actual)Interventional2016-09-30Completed
Effect of Plum-blossom Needle vs. Tropicamide Eye Drops on Juvenile Myopia: A Cross-over Single-blind Randomized Study [NCT03097198]98 participants (Anticipated)Interventional2016-12-31Recruiting
Efficiency and Safety of Phenylephrine and Tropicamide Used in Premature Retinopathy [NCT03448640]60 participants (Actual)Observational2016-01-15Completed
Efficacy and Safety of Mydriatic Microdrops Compared With Standard Drops for Retinopathy of Prematurity (ROP) Screening: a Pilot Randomized Clinical Trial [NCT04623684]Phase 425 participants (Actual)Interventional2020-03-24Completed
A Double-Masked, Active-Controlled Study of the Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Ophthalmic Solution Administered With a Microdose Dispenser for Dilation of the Pupil [NCT03751631]Phase 370 participants (Actual)Interventional2018-11-15Completed
Efficacy and Tolerance of Ophthalmic Insert Mydriasert® Versus Reference Treatment (Phenylephrine and Tropicamide Eyedrops) in Premature Newborns, Neonates and Infants Justifying a Mydriasis for a Bilateral Diagnosis Fundus [NCT00642135]Phase 380 participants (Actual)Interventional2006-01-31Terminated(stopped due to The total number of patients has been reached.)
A Study Evaluating Pupil Dilation Speed With the Micro-Array Print (MAP) Dispenser Comparing 2 Dosing Regimens of Tropicamide-Phenylephrine Fixed Combination Ophthalmic Solution [NCT04907474]Phase 460 participants (Actual)Interventional2021-05-24Completed
A New More Efficient Cycloplegia Scheme [NCT02177539]Phase 430 participants (Anticipated)Interventional2014-05-31Recruiting
A Single Centre, Controlled, Investigation to Evaluate the Performance of the Hyperspectral Camera for Retinal Non-invasive Examination Through the Observation of Retinal Oxygenation [NCT05566626]120 participants (Anticipated)Interventional2022-10-31Enrolling by invitation
Comparison of Conventional Instillation and Lower Conjunctival Fornix Packing in Mydriasis for Premature Infants [NCT00877175]Phase 425 participants (Actual)Interventional2009-03-31Completed
The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients, Pressure Control and Pupil Effects [NCT03959176]Phase 413 participants (Actual)Interventional2019-07-20Completed
Pilot Study of Prevention Myopia in Children With Low Concentration of Atropine [NCT00541177]Phase 460 participants (Anticipated)Interventional2007-04-30Recruiting
Clinical Investigation on the Blood Oxygenation at the Optic Nerve Head in Relation With Visual Field Loss in Fabry Patients [NCT02023086]8 participants (Actual)Observational [Patient Registry]2014-08-31Completed
The Wearing-Off Period of Pharmacological Dilation: An Addendum to the Management of Anisocoria [NCT05238233]Phase 411 participants (Actual)Interventional2022-04-01Completed
Subfoveal Choroidal Thickness After Femtosecond Laser-assisted Cataract Surgery for Age-related Cataracts [NCT02895074]40 participants (Actual)Interventional2014-08-31Completed
Evaluation of Light Sensitivity and Visual Acuity Changes as Consequence of Rigid Gas Permeable (RGP) Scleral Contact Lenses With a Passive Artificial Iris [NCT04040790]10 participants (Actual)Interventional2019-09-16Terminated(stopped due to Several reasons: Financing ended before all study assessments were performed, covid-19 delayed design, production and shipment of IMD, experience gained during the study made it clear that lens design should be changed)
Assessment of EyeCheckup as an Automated Diabetic Retinopathy Screening Tool [NCT04805541]900 participants (Anticipated)Observational2022-02-01Recruiting
Single Dose of 1% Tropicamide and 10% Phenylephrine for Pupillary Dilation [NCT00120432]Phase 380 participants (Actual)Interventional2004-12-31Completed
Changes in Vital Signs and Pupil Diameter Related to Pharmacologic Mydriasis in Premature Infants: A Randomized Double Blind Clinical Study [NCT04838665]Phase 460 participants (Actual)Interventional2011-09-30Completed
A Two-Phase, Double Blind, Placebo-Controlled, Randomized, Crossover Study of the Safety and Efficacy of Intra-Oral NH004 Films for the Short-Term Relief of Sialorrhea Symptoms in Parkinson's Disease Patients [NCT00761137]Phase 219 participants (Actual)Interventional2008-03-31Completed
A Randomized, Double-blind, Placebo-controlled, Crossover Study of the Safety and Efficacy of Tropicamide 1 mg Intra-oral Slow Dissolving Muco-adhesive Thin Films to Reduce Hypersalivation in PD Patients Manifesting Sialorrhea Complaints [NCT01844648]Phase 230 participants (Actual)Interventional2013-04-30Completed
Tropicamide Versus Cyclopentolate Objective Refraction in Pediatric Population [NCT05442801]Phase 455 participants (Actual)Interventional2022-03-01Completed
Descemet Endothelial Thickness Comparison Trial [NCT02373137]Phase 438 participants (Actual)Interventional2015-01-22Active, not recruiting
Efficacy and Safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening: a Non-inferiority Crossover Randomized Controlled Trial (MyMiROPS Trial) [NCT05043077]Phase 483 participants (Actual)Interventional2021-09-07Completed
Tropicamide Versus Cyclopentolate for Cycloplegic Refraction in Pediatric Patients With Esotropia: A Randomized Clinical Trial [NCT06077682]Phase 4100 participants (Anticipated)Interventional2023-09-01Recruiting
Comparison of the Effect of Tropicamide 0.5% and Tropicamide 1% on Intraocular Pressure, Pupil Size, Keratometry and Anterior Chamber Parameters in Patients With Type 1 and Type 2 Diabetes Mellitus [NCT04932213]Phase 398 participants (Actual)Interventional2021-07-07Completed
Efficacy and Safety Assessment of Intracameral Injection of T2380 in Cataract Surgery Versus Reference Group (Topical Mydriatics and Anaesthetic) [NCT02101359]Phase 3609 participants (Actual)Interventional2011-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00761137 (2) [back to overview]Percentage Change in Saliva Volume
NCT00761137 (2) [back to overview]Sialorrhea Visual Analogue Scale (VAS)
NCT02101359 (1) [back to overview]The Primary Efficacy Variable is Response Based on the Realisation of the Capsulorhexis Without Use of Any Additive Mydriatic Treatment.
NCT02373137 (13) [back to overview]Best Spectacle-Corrected Visual Acuity
NCT02373137 (13) [back to overview]Best Spectacle-Corrected Visual Acuity
NCT02373137 (13) [back to overview]Endothelial Cell Count
NCT02373137 (13) [back to overview]Adverse Events/Complication Rates
NCT02373137 (13) [back to overview]Best Spectacle-Corrected Visual Acuity
NCT02373137 (13) [back to overview]Corneal Higher-Order Aberrations
NCT02373137 (13) [back to overview]Corneal Higher-Order Aberrations
NCT02373137 (13) [back to overview]Endothelial Cell Count
NCT02373137 (13) [back to overview]Graft Failure/Graft Rejection
NCT02373137 (13) [back to overview]Graft Thickness
NCT02373137 (13) [back to overview]Interface Haze
NCT02373137 (13) [back to overview]Interface Haze
NCT02373137 (13) [back to overview]National Eye Institute - Visual Functioning Questionnaire (NEI-VFQ)
NCT03201562 (1) [back to overview]Proportion of Subjects With at Least a 3 Line (15 Letter) Improvement in Near Visual Acuity in the Study Eye
NCT03751098 (3) [back to overview]Proportion of Eyes Achieving Pupil Diameter 6.0 mm or Larger After Receipt of Each Medication
NCT03751098 (3) [back to overview]Proportion of Eyes Achieving Pupil Diameter 7.0 mm or Larger After Receipt of Each Medication
NCT03751098 (3) [back to overview]Change in Pupil Diameter From Baseline
NCT03751631 (3) [back to overview]Percentage of Eyes Achieving Pupil Diameter 6.0 mm or Larger After Receipt of Each Medication
NCT03751631 (3) [back to overview]Percentage of Eyes Achieving Pupil Diameter 7.0 mm or Larger After Receipt of Each Medication
NCT03751631 (3) [back to overview]Change in Pupil Diameter From Baseline
NCT05238233 (1) [back to overview]Number of Participants With Constricting Response to Pilocarpine 1% in the Pharmacologically Dilated Eye

Percentage Change in Saliva Volume

Saliva volume was measured at baseline and 75 minutes after treatment administration. Volumes were measured by using cotton rolls placed near each Stenton duct and below the tongue for 5 minutes; cotton rolls were centrifuged and the volume of saliva determined. (NCT00761137)
Timeframe: Before and 75 minutes after treatment administration

Interventionpercentage change of saliva volume (Median)
Tropicamide - Placebo-5
Tropicamide - 0.3 mg-27
Tropicamide - 1 mg-33
Tropicamide 3 mg-20

[back to top]

Sialorrhea Visual Analogue Scale (VAS)

Saliva buccal assessment was evaluated by an VAS scale before, and 15, 30, 45, 60, 90, and 120 min after treatment administration. Subjects were asked to rate how much saliva they perceived in their buccal cavity on an unmarked 0 to 10 cm line, higher scores meaning greater perceived buccal saliva levels. (NCT00761137)
Timeframe: Before and 120 min after treatment administration

Interventioncm on VAS (Mean)
Tropicamide - Placebo-0.55
Tropicamide - 0.3 mg-1.08
Tropicamide - 1 mg-1.53
Tropicamide 3 mg-0.81

[back to top]

The Primary Efficacy Variable is Response Based on the Realisation of the Capsulorhexis Without Use of Any Additive Mydriatic Treatment.

(NCT02101359)
Timeframe: Day 0

Interventionpercentage of responders (Number)
T238098.9
Reference Group94.7

[back to top]

Best Spectacle-Corrected Visual Acuity

The BSCVA was recorded at 4 meters by a masked refractionist certified for the study using a protocol adapted from the Age-Related Eye Disease Study using Early Treatment Diabetic Retinopathy Study charts: chart R(2110), chart 1(2111), and chart 2(2112) (Precision Vision, Woodstock, IL). (NCT02373137)
Timeframe: 24 Months

InterventionLogMar (Mean)
UT-DSAEK0.15
DMEK0.09

[back to top]

Best Spectacle-Corrected Visual Acuity

The BSCVA was recorded at 4 meters by a masked refractionist certified for the study using a protocol adapted from the Age-Related Eye Disease Study using Early Treatment Diabetic Retinopathy Study charts: chart R(2110), chart 1(2111), and chart 2(2112) (Precision Vision, Woodstock, IL). (NCT02373137)
Timeframe: 6 months

InterventionlogMAR (Mean)
UT-DSAEK0.22
DMEK0.05

[back to top]

Endothelial Cell Count

(NCT02373137)
Timeframe: 24 months

Interventioncells/mm^2 (Mean)
UT-DSAEK1626
DMEK1400

[back to top]

Adverse Events/Complication Rates

composite measure (NCT02373137)
Timeframe: 3, 6, 12, 24 months

,
Interventionnew adverse events reported (Number)
Adverse Events at 3 monthsAdverse Events at 6 monthsAdverse Events at 12 monthsAdverse Events at 24 months
DMEK6540
UT-DSAEK4410

[back to top]

Best Spectacle-Corrected Visual Acuity

The BSCVA was recorded at 4 meters by a masked refractionist certified for the study using a protocol adapted from the Age-Related Eye Disease Study using Early Treatment Diabetic Retinopathy Study charts: chart R(2110), chart 1(2111), and chart 2(2112) (Precision Vision, Woodstock, IL). (NCT02373137)
Timeframe: 3 and 12 months

,
InterventionlogMAR (Mean)
3 Months12 Months
DMEK0.110.04
UT-DSAEK0.240.16

[back to top]

Corneal Higher-Order Aberrations

As measured by Pentacam (NCT02373137)
Timeframe: 24 months

,
Interventionroot mean square in micrometers (Mean)
24 Months Anterior Cornea 4.0-mm24 Months Posterior Cornea 4.0-mm24 Months Anterior Cornea 6.0-mm24 Months Posterior Cornea 6.0-mm
DMEK0.2110.0860.6790.260
DSAEK0.2150.1550.7070.450

[back to top]

Corneal Higher-Order Aberrations

Corneal anterior and posterior surface higher-order aberrations (HOA) were measured with Scheimpflug imaging (Pentacam) before surgery and at 3, 6, and 12 months post-operatively. Zernike orders 3-8 were calculated at 4.0- and 6.0-mm-diameter optical zones. The results reported here represent total HOA (Sum of Zernike orders 3-8). Note a single observation was not available for one eye in the DMEK group at 6 months, this was analyzed with last observation carried forward. (NCT02373137)
Timeframe: 3, 6, 12 months

,
Interventionroot mean square in micrometers (Mean)
3 Months Anterior Cornea 4.0-mm3 Months Posterior Cornea 4.0-mm3 Months Anterior Cornea 6.0-mm3 Months Posterior Cornea 6.0-mm6 Months Anterior Cornea 4.0-mm6 Months Posterior Cornea 4.0-mm6 Months Anterior Cornea 6.0-mm6 Months Posterior Cornea 6.0-mm12 Months Anterior Cornea 4.0-mm12 Months Posterior Cornea 4.0-mm12 Months Anterior Cornea 6.0-mm12 Months Posterior Cornea 6.0-mm
DMEK0.2880.1160.8290.3460.2430.0950.7240.2880.2410.0980.7230.284
UT-DSAEK0.2740.2170.8970.6210.2300.1790.7390.5050.2280.1590.7250.459

[back to top]

Endothelial Cell Count

(NCT02373137)
Timeframe: 3, 6, 12 months

,
Interventioncells/mm^2 (Mean)
3 Months6 Months12 Months
DMEK203719631855
UT-DSAEK211421132070

[back to top]

Graft Failure/Graft Rejection

(NCT02373137)
Timeframe: Baseline 12 months

,
Interventioneyes (Count of Units)
Graft RejectionGraft Failure
DMEK01
UT-DSAEK01

[back to top]

Graft Thickness

As measured by Optical coherence tomography (OCT) and Pachymetry (NCT02373137)
Timeframe: 3, 6, 12, 24 months

,
Interventionroot mean square in micrometers (Mean)
3 months6 months12 months24 months
DMEK516.5519.67521.36526.88
UT-DSAEK589.36592.24585.96593.67

[back to top]

Interface Haze

As measured by Pentacam densitometry (NCT02373137)
Timeframe: 24 months

,
Interventioneyes (Number)
Mild Interface Haze at 24 monthsModerate Interface Haze at 24 monthsSevere Interface Haze at 24 months
DMEK000
UT-DSAEK010

[back to top]

Interface Haze

As measured by Pentacam densitometry (NCT02373137)
Timeframe: 3, 6, 12 months

,
Interventioneyes (Number)
Mild Interface Haze at 3 monthsModerate Interface Haze at 3 monthsSevere Interface Haze at 3 monthsMild Interface Haze at 6 monthsoderate Interface Haze at 6 monthsSevere Interface Haze at 6 monthsMild Interface Haze at 12 monthsoderate Interface Haze at 12 monthsSevere Interface Haze at 12 months
DMEK100100000
UT-DSAEK200210000

[back to top]

National Eye Institute - Visual Functioning Questionnaire (NEI-VFQ)

"The National Eye Institute has developed the validated Visual Functioning Questionnaire (NEI-VFQ) to assess the effect of ocular conditions and vision on patient quality of life. The answers to the questionnaire are transformed into sub-scales, including: general health, general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision. Participants are assigned a numerical value for each sub-scale based on their answers between 0-100, where higher numbers indicate better visual function. These sub-scales are then combined according to National Eye Institute guidelines into an overall composite score for each participant. This overall composite score is also on a scale of 0-100, where higher numbers indicate better visual function.~Composite score based on National Eye Institute guidelines." (NCT02373137)
Timeframe: Baseline, 12 months

,
InterventionComposite scores on a scale (Mean)
Baseline12 Months
DMEK72.387.3
UT-DSAEK72.585.9

[back to top]

Proportion of Subjects With at Least a 3 Line (15 Letter) Improvement in Near Visual Acuity in the Study Eye

Proportion of subjects with at least a 3 line (15 letter) improvement in near visual acuity in the study eye at 1 hour post-treatment in the mITT population (NCT03201562)
Timeframe: 1 hour post-treatment

Interventionpercentage of participants (Number)
Aceclidine+Tropicamide Combination47.22
Aceclidine47.22
Vehicle2.38

[back to top]

Proportion of Eyes Achieving Pupil Diameter 6.0 mm or Larger After Receipt of Each Medication

The percent of eyes with pupil diameter 6.0 mm or larger as measured using pupillometry in highly photopic conditions. As this is a cross-over study, each of the 69 participants received each medication. Data is reported separately for the right and left eyes of the 69 participants. A higher percentage indicates a better outcome. (NCT03751098)
Timeframe: 35 minutes after initial dose

Interventionpercentage of eyes (Number)
TR/PE - Right Eye92.8
TR/PE - Left Eye94.2
Placebo - Right Eye0
Placebo - Left Eye0

[back to top]

Proportion of Eyes Achieving Pupil Diameter 7.0 mm or Larger After Receipt of Each Medication

The percent of eyes with pupil diameter 7.0 mm or larger as measured using pupillometry in highly photopic conditions. As this is a cross-over study, each of the 69 participants received each solution. Data is reported separately for the right and left eyes of the 69 participants. A higher percentage indicates a better outcome. (NCT03751098)
Timeframe: 35 minutes after initial dose

Interventionpercentage of eyes (Number)
TR/PE - Right Eye69.6
TR/PE - Left Eye68.1
Placebo - Right Eye0
Placebo - Left Eye0

[back to top]

Change in Pupil Diameter From Baseline

"Difference in 35-minute pupil diameter vs. baseline measured using pupillometry in highly photopic conditions.~Pupil diameter is reported in millimeters. For the change in pupil diameter, larger measurements indicate a better outcome." (NCT03751098)
Timeframe: 35 minutes after initial dose

,,,
Interventionmillimeters (Mean)
Change in 35-minute pupil diameterBaseline pupil diameter35-minutes pupil diameter
Placebo - Left Eye0.0322.5592.590
Placebo - Right Eye0.1342.6322.766
TR/PE - Left Eye4.7792.5247.304
TR/PE - Right Eye4.7472.5977.344

[back to top]

Percentage of Eyes Achieving Pupil Diameter 6.0 mm or Larger After Receipt of Each Medication

The percent of eyes with pupil diameter 6.0 mm or larger as measured using pupillometry in highly photopic conditions. As this is a cross-over study, each of the 62 participants received each medication. Data is reported separately for the right and left eyes of the 62 participants. A higher percentage indicates a better outcome. (NCT03751631)
Timeframe: 35 minutes after initial dose

Interventionpercentage of eyes (Number)
TR/PE - Right Eye95.2
TR/PE - Left Eye93.5
TR - Right Eye79.0
TR - Left Eye77.4
PE - Right Eye1.6
PE - Left Eye1.6

[back to top]

Percentage of Eyes Achieving Pupil Diameter 7.0 mm or Larger After Receipt of Each Medication

The percent of eyes with pupil diameter 7.0 mm or larger as measured using pupillometry in highly photopic conditions. As this is a cross-over study, each of the 62 participants received each medication. Data is reported separately for the right and left eyes of the 62 participants. A higher percentage indicates a better outcome. (NCT03751631)
Timeframe: 35 minutes after initial dose

Interventionpercentage of eyes (Number)
TR/PE - Right Eye67.7
TR/PE - Left Eye67.7
TR - Right Eye43.5
TR - Left Eye41.9
PE - Right Eye0
PE - Left Eye0

[back to top]

Change in Pupil Diameter From Baseline

"Difference in 35-minute pupil diameter vs. baseline measured using pupillometry in highly photopic conditions.~Pupil diameter is reported in millimeters. For the change in pupil diameter, larger measurements indicate a better outcome." (NCT03751631)
Timeframe: 35 minutes after initial dose

,,,,,
Interventionmillimeters (Mean)
Baseline pupil diameter35-minute pupil diameterChange in 35-minute pupil diameter
PE - Left Eye2.5843.5520.969
PE - Right Eye2.6513.3880.737
TR - Left Eye2.5696.6904.121
TR - Right Eye2.6576.7624.105
TR/PE - Left Eye2.5837.3294.746
TR/PE - Right Eye2.6727.3014.629

[back to top]

Number of Participants With Constricting Response to Pilocarpine 1% in the Pharmacologically Dilated Eye

Measurement of pupil diameter (NCT05238233)
Timeframe: 4 hours

InterventionParticipants (Count of Participants)
Eye Dilation and Constriction3

[back to top]